Use of antiparkinsonian medication tied to acquired premature ejaculation
Individuals taking antiparkinsonian drugs have developed ejaculatory dysfunction, which suggests a possible medication effect, in a case series of Parkinson’s disease (PD) patients with acquired premature ejaculation (PE).
The mean age of PD onset was 53.3±12.7 years (range, 38–77 years), while sexual problems started to appear 4.0±3.1 years later. Patients had a mean 7.3 min (range, 2–20 min) of intravaginal ejaculation latency (IELT) before the onset of acquired PE.
Of note, there was an abrupt appearance of the ejaculatory dysfunction as characterized by a dramatically shortened IELT in all patients. Furthermore, three patients had an ejaculation prior to vaginal penetration, which hampered sexual intercourse.
In some patients, two additional sexual problems occurred: four had erectile dysfunction, five had libido changes, four had increase desire and one had reduced desire.
In this study, the investigators described eight PD patients who asked for a sexological consultation between 2008 and 2014 because of new-onset of PE. Patients were diagnosed with acquired PE according to the DSM-V criteria and the International Society for Sexual Medicine committee. Demographic, medical and sexual-related data of patients were retrieved and analysed.
Acquired PE is defined as “a male sexual dysfunction characterized by the development of a clinically significant and bothersome reduction in ejaculation latency time in men with previous normal ejaculatory experiences, often to about 3 minutes or less, the inability to delay ejaculation on all or nearly all vaginal penetrations, and the presence of negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.” [Transl Androl Urol 2016;5:434-449]
“PE has been reported in 40.6–51.5 percent of men affected by PD,” the investigators said. “However, this nonmotor sexual complaint has not been studied in detail.”